<DOC>
	<DOCNO>NCT01756989</DOCNO>
	<brief_summary>The purpose study determine whether initial local irradiation topotecan follow oral antiangiogenic drug , thalidomide , celecoxib etoposide effective treatment pediatric diffuse brainstem tumor .</brief_summary>
	<brief_title>ANGIOCOMB Antiangiogenic Therapy Pediatric Patients With Diffuse Brain Stem Thalamic Tumors</brief_title>
	<detailed_description>All pediatric patient ( age 1-16 yr ) newly diagnose diffuse brain stem tumor inoperable thalamic tumor infiltrate brain stem pediatric oncology unit Denmark , Finland , Iceland , Norway Sweden eligible . A possible tumor biopsy histologic finding take account . The diagnosis base MRI . The patient give conventional local radiotherapy 54 Gy , patient also receive topotecan radiosensitizer . Within four week complete radiotherapy , investigational drug start . If family reason refuse radiotherapy , investigational therapy may still consider . The guardian age-appropriate patient ask write informed consent . If family willing participate trial , patient treat accord currently best available therapy ( mean RT without topotecan palliative therapy ) . The family right withdraw study , whenever wish . Brain MRI initial diagnosis , start triple medication , q 3 mo initiation triple medication , otherwise clinically indicate . In case decide continue medication progression MRI , repeat MRIs recommend every month . MRI also register , feasible , discontinuation medication . The clinical follow-up , well MRI follow-up , clinical indication continue also discontinuation therapy . PET-CT and/or MRI spectroscopy consider diagnosis 3 mo start triple medication .</detailed_description>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>pediatric diffuse brainstem tumor wish family need strong painrelievers decrease level consciousness inability swallow .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>